Natural and long-lasting cellular immune responses against influenza in the M2e-immune host

Mucosal Immunology

Volumn 6, Issue 2, 2013, Pages 276-287

  Schotsaert, M ^a,b   Ysenbaert, T ^a,b   Neyt, K ^a,b   Ibanez L I ^a,b   Bogaert, P ^a,b   Schepens, B ^a,b   Lambrecht, B N ^a,b   Fiers, W ^a,b   Saelens, X ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HN PROTEIN; IMMUNOGLOBULIN G; INFLUENZA VACCINE; MATRIX PROTEIN 2 EXTRACELLULAR DOMAIN VIRUS LIKE PARTICLE VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; VIRUS VACCINE;

2009 H1N1 INFLUENZA; ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; FEMALE; INFECTION PREVENTION; INFLUENZA A; INFLUENZA A (H3N2); INFLUENZA A (H3N3); INFLUENZA VACCINATION; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RECURRENT INFECTION; SEROCONVERSION; VIRUS INACTIVATION;

EID: 84874099731     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2012.69     Document Type: Article

References (46)

1. Bodewes, R. et al. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS One 4, e5538 (2009).
2. Brammer, L., Budd, A. & Cox, N. Seasonal and pandemic influenza surveillance considerations for constructing multicomponent systems. Influenza Other Respir. Viruses 3, 51-58 (2009).
3. Neumann, G., Noda, T. & Kawaoka, Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459, 931-939 (2009).
4. Gotch, F., McMichael, A., Smith, G. & Moss, B. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. J. Exp. Med. 165, 408-416 (1987).
5. Moskophidis, D. & Kioussis, D. Contribution of virus-specific CD8+ cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model. J. Exp. Med. 188, 223-232 (1998).
6. Topham, D. J., Tripp, R. A. & Doherty, P. C. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J. Immunol. 159, 5197-5200 (1997).
7. Bodewes, R. et al. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J. Virol. 85, 2695-2702 (2011).
8. Bodewes, R. et al. Vaccination with whole inactivated virus vaccine affects the induction of heterosubtypic immunity against influenza virus A/H5N1 and immunodominance of virus-specific CD8+ T-cell responses in mice. J. Gen. Virol. 91, 1743-1753 (2010).
9. Bodewes, R., Kreijtz, J. H. & Rimmelzwaan, G. F. Yearly influenza vaccinations: a double-edged sword? Lancet Infect. Dis. 9, 784-788 (2009).
10. Bodewes, R. et al. Annual vaccination against influenza virus hampers development of virus-specific CD8 T cell immunity in children. J. Virol. 85, 11995-12000 (2011).
11. Fiore, A. E. et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm. Rep. 57, 1-60 (2008).
12. Neirynck, S. et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5, 1157-1163 (1999).
13. Schotsaert, M., De Filette, M., Fiers, W. & Saelens, X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev. Vaccines 8, 499-508 (2009).
14. De Filette, M. et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337, 149-161 (2005).
15. Chen, W., Anton, L. C., Bennink, J. R. & Yewdell, J. W. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 12, 83-93 (2000).
16. Feng, J. et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol. J. 3, 102 (2006).
17. Moyron-Quiroz, J. E. et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat. Med. 10, 927-934 (2004).
18. Kreijtz, J. H. et al. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus. Vaccine 27, 4983-4989 (2009).
19. El Bakkouri, K. et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186, 1022-1031 (2011).
20. Roose, K., Fiers, W. & Saelens, X. Pandemic preparedness: toward a universal influenza vaccine. Drug News Perspect. 22, 80-92 (2009).
21. Song, J. M. et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 6, e14538 (2011).
22. Jegerlehner, A., Schmitz, N., Storni, T. & Bachmann, M. F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172, 5598-5605 (2004).
23. Song, J. M., Van Rooijen, N., Bozja, J., Compans, R. W. & Kang, S. M. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc. Natl. Acad. Sci. USA 108, 757-761 (2011).
24. Ernst, W. A. et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24, 5158-5168 (2006).
25. Bodewes, R. et al. Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands. Clin. Vaccine Immunol. 18, 469-476 (2011).
26. Hoft, D. F. et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J. Infect. Dis. 204, 845-853 (2011).
27. Hillaire, M. L. et al. Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J. Gen. Virol. 92, 2339-2349 (2011).
28. Belz, G. T., Xie, W., Altman, J. D. & Doherty, P. C. A previously unrecognized H-2D(b)-restricted peptide prominent in the primary influenza A virusspecific CD8(+) T-cell response is much less apparent following secondary challenge. J. Virol. 74, 3486-3493 (2000).
29. Rodriguez, F., Harkins, S., Slifka, M. K. & Whitton, J. L. Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J. Virol. 76, 4251-4259 (2002).
30. Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181-193 (2011).
31. Schulman, J. L. & Kilbourne, E. D. Induction of partial specific heterotypic immunity in mice by a single infection with influenza a virus. J. Bacteriol. 89, 170-174 (1965).
32. GeurtsvanKessel, C. H. et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J. Exp. Med. 206, 2339-2349 (2009).
33. Halle, S. et al. Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J. Exp. Med. 206, 2593-2601 (2009).
34. Moyron-Quiroz, J. E. et al. Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity 25, 643-654 (2006).
35. Stohr, K. Vaccinate before the next pandemic? Nature 465, 161 (2010).
36. Carrat, F., Lavenu, A., Cauchemez, S. & Deleger, S. Repeated influenza vaccination of healthy children and adults: borrow now, pay later? Epidemiol. Infect. 134, 63-70 (2006).
37. Corbeel, L. Should healthy children be vaccinated against influenza? Comments about this query. Eur. J. Pediatr. 166, 629-631 (2007).
38. Hobson, D., Curry, R. L., Beare, A. S. & Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond) 70, 767-777 (1972).
39. Bhat, N. et al. Influenza-associated deaths among children in the United States, 2003-2004. N. Engl. J. Med. 353, 2559-2567 (2005).
40. Esposito, S. & Principi, N. The rational use of influenza vaccines in healthy children and children with underlying conditions. Curr. Opin. Infect. Dis. 22, 244-249 (2009).
41. Daum, L. T. et al. Genetic and antigenic analysis of the first A/New Caledonia/20/99-like H1N1 influenza isolates reported in the Americas. Emerg. Infect. Dis. 8, 408-412 (2002).
42. Karasin, A. I., West, K., Carman, S. & Olsen, C. W. Characterization of avian H3N3 and H1N1 influenza A viruses isolated from pigs in Canada. J. Clin. Microbiol. 42, 4349-4354 (2004).
43. Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493-497 (1938).
44. Romano, M. et al. Induction of in vivo functional Db-restricted cytolytic T cell activity against a putative phosphate transport receptor of Mycobacterium tuberculosis. J. Immunol. 172, 6913-6921 (2004).
45. Barber, D. L., Wherry, E. J. & Ahmed, R. Cutting edge: rapid in vivo killing by memory CD8 T cells. J. Immunol. 171, 27-31 (2003).
46. Liu, F. & Whitton, J. L. Cutting edge: re-evaluating the in vivo cytokine responses of CD8+ T cells during primary and secondary viral infections. J. Immunol. 174, 5936-5940 (2005).